LSE:PRTC (PureTech Health plc)
About PRTC
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, neurological & neuropsychological disorders, among others. It operates in following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of society's healthcare needs.
PureTech Health plc (LSE: PRTC) Latest News

Investing Articles
3 shares to buy with £10,000 today

Page
Investing in Biotech: Top UK Biotech Stocks in 2022
Investing Articles
These 2 UK shares have updated investors. Here are the key points
Investing Articles
1 FTSE small-cap biotech stock I’d buy now
Investing Articles
Here’s why I think this FTSE 250 biotech growth stock could be set to climb higher
Investing Articles
Why I might buy this soaring stock alongside the Glaxo (GSK) share price
Investing Articles
I see growth in the pipeline at this FTSE 250 biotech stock
